13,078
Views
121
CrossRef citations to date
0
Altmetric
Review

How to prepare a systematic review of economic evaluations for informing evidence-based healthcare decisions: data extraction, risk of bias, and transferability (part 3/3)

, , , , &
Pages 723-732 | Received 26 Apr 2016, Accepted 07 Oct 2016, Published online: 21 Oct 2016

References

  • Mastrigt GAPGH, Arts JJC, Broos PH, et al. How to prepare a systematic review of economic evaluations for informing evidence-based healthcare decisions: a five-step approach (part 1 of 3). doi:10.1080/14737167.2016.1246960. [Epub ahead of print].
  • Terrace L. Development and validation of an international appraisal instrument for assessing the quality of clinical practice guidelines: the AGREE project. Qual Saf Health Care. 2003;12:18–23.
  • Brouwers MC, Kho ME, Browman GP, et al. AGREE II: advancing guideline development, reporting and evaluation in health care. Can Med Assoc J. 2010;182(18):E839–E842.
  • cancer, C.p.a. AGREE II domains, items, examples and resources. [ cited 2016 02 19]. Available from: http://www.cancerview.ca/cv/portal/Home/TreatmentAndSupport/TSProfessionals/ClinicalGuidelines/GRCMain/GRCAGREEII/GRCAGREEIIDomain3Rigour?_afrLoop=7202305453745000&jsessionid=24h456yAq7d254qi0ILI7VsmaXiA_PrK-x3k9VkKOzLOzM5cClFs%21-1278458346&lang=en&_afrWindowMode=0&_adf.ctrl-state=y4y9grh4m_4
  • Drummond, M.F., Sculpher, M.J., Claxton, K, et al. Methods for the economic evaluation of health care programmes. Oxford: Oxford university press; 2015.
  • Brown GW. On small-sample estimation. Ann Math Statist. 1947;18(4):582–585.
  • Evers SM, Hiligsmann M, Adarkwah CC. Risk of bias in trial-based economic evaluations: identification of sources and bias-reducing strategies. Psychol Health. 2015;30(1):52–71.
  • Husereau D, Drummond M, Petrou S, et al. Consolidated health economic evaluation reporting standards (CHEERS) statement. BMC Med. 2013;11(1):80.
  • Rennie D, Luft HS. Pharmacoeconomic analyses: making them transparent, making them credible. JAMA. 2000;283(16):2158–2160.
  • Higgins JP, Altman DG, Gotzsche PC, et al. The Cochrane collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.
  • Begg C, Cho M, Eastwood S, et al. Improving the quality of reporting of randomized controlled trials: the CONSORT statement. JAMA. 1996;276(8):637–639.
  • Von Elm E, Altman DG, Egger M, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Prev Med. 2007;45(4):247–251.
  • Schünemann H, Hill S, Guyatt G, et al. The GRADE approach and Bradford Hill’s criteria for causation. J Epidemiol Community Health. 2011;65(5):392–395.
  • Grant MJ, Booth A. A typology of reviews: an analysis of 14 review types and associated methodologies. Health Info Libr J. 2009;26(2):91–108.
  • Akers J, Aguiar-Ibáñez R, Baba-Akbari Sari A. CRD’s guidance for undertaking reviews in health care. York (UK): Centre for Reviews and Dissemination (CRD); 2009.
  • Higgins JP, Green S. Cochrane handbook for systematic reviews of interventions. Vol. 5. Chichester: Wiley Online Library; 2008.
  • Mlika-Cabanne N, Harbour R, De Beer H, et al. Sharing hard labour: developing a standard template for data summaries in guideline development. BMJ Qual Saf. 2011;20(2):141–145.
  • De Kinderen RJ, Lambrechts DAJE, Wijnen BFM, et al. An economic evaluation of the ketogenic diet versus care as usual in children and adolescents with intractable epilepsy: an interim analysis. Epilepsia. 2016;57(1):41–50.
  • Walker, D.G., Wilson, R.F, Sharma, R, et al. Best practices for conducting economic evaluations in health care: a systematic review of quality assessment tools. The Johns Hopkins University Evidence-based Practice Center. Rockville (MD): Agency for Healthcare Research and Quality (US); 2012.
  • Sculpher M, Fenwick E, Claxton K. Assessing quality in decision analytic cost-effectiveness models. Pharmacoeconomics. 2000;17(5):461–477.
  • Philips, Z, Ginnelly L, Sculpher M, et al. Good practice guidelines for decision-analytic modelling in health technology assessment. Pharmacoeconomics. 2006;24(4):355–371.
  • Caro JJ, Eddy DM, Kan H, et al. Questionnaire to assess relevance and credibility of modeling studies for informing health care decision making: an ISPOR-AMCP-NPC good practice task force report. Value Health. 2014;17(2):174–182.
  • Drummond MF, Jefferson T. Guidelines for authors and peer reviewers of economic submissions to the BMJ. BMJ. 1996;313(7052):275–283.
  • Evers S, Goossens M, De Vet H, et al. Criteria list for assessment of methodological quality of economic evaluations: consensus on health economic criteria. Int J Technol Assess Health Care. 2005;21(2):240–245.
  • Odnoletkova, I, Goderis, G, Pil, L, et al. Cost-effectiveness of therapeutic education to prevent the development and progression of type 2 diabetes: systematic review. J Diabetes Meta.b 2014;5:438 doi:10.4172/2155-6156.1000438
  • Consensus Health Economic Criteria - CHEC list Available from: https://hsr.mumc.maastrichtuniversity.nl/consensus-health-economic-criteria-chec-list
  • Excellence, N.i.f.C. Developing NICE guidelines: the manual; 2014; Available from: http://www.nice.org.uk/article/PMG20/chapter/7-Incorporating-economic-evaluation
  • Brunetti M, Shemilt I, Pregno S, et al. GRADE guidelines: 10. Considering resource use and rating the quality of economic evidence. J Clin Epidemiol. 2013;66(2):140–150.
  • Brunetti, M, Ruiz, F, Lord, J, et al. Grading economic evidence. Oxford: Wiley-Blackwell; 2010.
  • Knies S, Ament AJHA, Evers SMAA, et al. The transferability of economic evaluations: testing the model of Welte. Value Health. 2009;12(5):730–738.
  • Goeree R, He J, O’Reilly D, et al. Transferability of health technology assessments and economic evaluations: a systematic review of approaches for assessment and application. CEOR. 2011;3:89.
  • Essers BA, Seferina SC, Tjan-Heijnen VCG, et al. Transferability of model‐based economic evaluations: the case of trastuzumab for the adjuvant treatment of HER2‐positive early breast cancer in The Netherlands. Value Health. 2010;13(4):375–380.
  • Welte R, Feenstra T, Jager H, et al. A decision chart for assessing and improving the transferability of economic evaluation results between countries. Pharmacoeconomics. 2004;22(13):857–876.
  • Müller, D, Gerber-Grote, A, Stollenwerk, B, et al. Reporting health care decision models: a prospective reliability study of a multidimensional evaluation framework. Expert Rev Pharmacoecon Outcomes Res. 2016;16(5);1–9.
  • Thielen WF, Burgers LT, Bramer WM, et al., v.M.G.; How to prepare a systematic review of economic evaluations for informing evidence-based healthcare decisions: database selection and search strategy development. doi:10.1080/14737167.2016.1246962. [Epub ahead of print].
  • Drummond M, Barbieri M, Cook J, et al. Transferability of economic evaluations across jurisdictions: ISPOR good research practices task force report. Value Health. 2009;12(4):409–418.
  • Grutters JP, Seferina SC, Tjan-Heijnen VCG, et al. Bridging trial and decision: a checklist to frame health technology assessments for resource allocation decisions. Value Health. 2011;14(5):777–784.
  • Adarkwah, C.C, van Gils, P.F, Hiligsmann, M, et al. Risk of bias in model-based economic evaluations: the ECOBIAS checklist. Expert Rev Pharmacoecon Outcomes Res. 2016;16(4);1–11.
  • Vemer, P, Ramos, I.C., van Voorn, G.A.K., et al. AdViSHE: a validation-assessment tool of health-economic models for decision makers and model users. Pharmacoeconomics. 2016;34:349. doi:10.1007/s40273-015-0327-2